The first dominant SARS‐CoV‐2 Omicron variant BA. 1 harbours 35 mutations in its Spike
protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its …

Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …

Abstract The SARS-CoV-2 Omicron variant was first identified in November 2021 in
Botswana and South Africa,–. It has since spread to many countries and is expected to …

Emerging strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the
causative agent of the coronavirus disease 2019 (COVID-19) pandemic, that show …

Vaccination-based exposure to spike protein derived from early SARS-CoV-2 sequences is
the key public health strategy against COVID-19. Successive waves of SARS-CoV-2 …

The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in
the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising …

Vaccines based on the spike protein of SARS-CoV-2 are a cornerstone of the public health
response to COVID-19. The emergence of hypermutated, increasingly transmissible variants …

SARS-CoV-2 Omicron rapidly outcompeted other variants and currently dominates the
COVID-19 pandemic. Its enhanced transmission and immune evasion are thought to be …

The Omicron variant of SARS-CoV-2 recently swept the globe and showed high level of
immune evasion. Here, we generate an Omicron-specific lipid nanoparticle (LNP) mRNA …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) keeps evolving and
mutating into newer variants over time, which gain higher transmissibility, disease severity …